Unimed Pharmaceuticals, Inc., a wholly owned subsidiary of Solvay Pharmaceuticals, Inc., focuses on drugs with multiple indications in the therapeutic areas of men's health, HIV and other infectious diseases. Unimed Pharmaceuticals has expertise in ethical drug development, marketing and sales.
Established in 1906, PARI was founded by Paul Ritzau in Wuppertal, Germany. Business with hospitals then prompted the company to concentrate on medical equipment. PARI initially developed products for Balneotherapy: bathing in thermal or mineral waters for improved health. Those early devices evolved and were gradually replaced by today's modern, specialized devices for treatment of respiratory diseases. As generations have passed, PARI has created the conditions for ensuring the continuity and reliability of its research and commercial activities. This strong foundation underlies their stability and independence.
Medical Developments International Limited (MDI) is a leading Australian healthcare company in pain relief and respiratory medicine. MDI has a range of products for pain management, asthma, oxygen delivery and veterinary use. MDI's aim is to commercialise these products internationally. MDI is based in Australia and consists of three major business divisions:
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them. Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufacturers the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.Pari.com
LAB International is an integrated drug development company focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies. LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with 74.5 million shares outstanding.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory